CClinicalTrials.gg
Not yet recruitingNCT06162273Updated Dec 8, 2023

An Exploratory Study of Iliac Artery Branch Stent for Internal Iliac Artery Reconstruction in Abdominal Aortic Aneurysm/Iliac Aneurysm Repair

An observational study in Aortic Aneurysm, Abdominal and Iliac Aneurysm, sponsored by RenJi Hospital. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2023-12-08.

Sponsored by RenJi Hospital · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
40
Ages
18 Years to 85 Years
Sex
All
01

Study summary

The purpose of this study is to evaluate the efficacy and safety of IBD stent of Shenzhen Xianjian Company and IBE stent of American Gore company in the treatment of abdominal aortic aneurysm/iliac aneurysm reconstruction of internal iliac artery

Read the detailed description

This study is a prospective observational exploratory cohort study without a control group. As a single-group target value validation study, the main evaluation indicator is the primary patency rate one year after surgery. As an exploratory study, considering the enrollment ability to facilitate data analysis, 40 subjects are enrolled in the final study, and 20 are expected to be included in each study. All enrolled patients will be followed for 12 months for CTA to assess primary patency. Telephone follow-up was conducted at 1, 3, 6, and 12 months for adverse events.

02

Conditions studied

  • Aortic Aneurysm, Abdominal
  • Iliac Aneurysm

Keywords

  • Iliac artery branch stent
  • Patency rate
  • Internal iliac artery
03

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with iliac aneurysms/abdominal aortic aneurysms requiring iliac branch stents

Inclusion criteria

  1. Patients with iliac aneurysms combined with or without abdominal aortic aneurysms and internal iliac arteries reconstructed with iliac branch stents;
  2. Male or female ≥18 years old, ≤85 years old;
  3. Life expectancy > 2 years;
  4. The patient signed the informed consent voluntarily and was able to comply with the treatment plan and complete the follow-up and examination as planned.

Exclusion criteria

Exclusion Criteria:

  1. Fungal or ruptured aneurysm
  2. Known complications of thoracic aortic aneurysm require interventional treatment
  3. American Association of Anesthesiologists (ASA) Grade V
  4. Creatinine > 2.5mg/dL or dialysis patients
  5. NYHA Grade IV heart failure
  6. Intercalation, severe calcification, or anchoring area with thrombosis
  7. Severe curvature or narrowing of the iliac and/or femoral arteries, resulting in difficulty in stent delivery
  8. Conduct another device or drug study within 1 year of treatment
  9. Systemic infection
  10. Combined with connective tissue disease
  11. Known history of drug use
  12. Known allergies or allergies to equipment materials
04

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
40 participants (estimated)
Patient registry
No

Groups and cohorts

  • IBD stent of Shenzhen Xianjian Company and IBE stent of American Gore company

    Patients underwent endovascular treatment for reconstruction of internal iliac artery in abdominal aortic aneurysm/iliac aneurysm repair. The lesion will be treated by IBD stent of Shenzhen Xianjian Company and IBE stent of American Gore Company.

    Device: IBD stent of Shenzhen Xianjian Company and IBE stent of American Gore company

Interventions

  • DeviceIBD stent of Shenzhen Xianjian Company and IBE stent of American Gore company

    Patients underwent endovascular treatment for reconstruction of internal iliac artery in abdominal aortic aneurysm/iliac aneurysm repair. The lesion will be treated by IBD stent of Shenzhen Xianjian Company and IBE stent of American Gore Company.

05

What researchers measure

Primary outcomes

  1. Primary patency

    CTA showed patency of the preserved internal iliac artery.

    Time frame: 12-month

Secondary outcomes

  1. New hip lameness

    New hip lameness is defined as new hip claudication in the lateral body treated with an iliac artery branch stent.

    Time frame: 12-month

  2. Internal leakage

    Internal leakage is defined as any type of internal leakage that occurs during the follow-up period.

    Time frame: 12-month

  3. Aneurysmal enlargement

    Aneurysm enlargement is defined as having a larger aneurysm diameter during follow-up than before surgery.

    Time frame: 12-month

  4. Aneurysm rupture

    Ruptured aneurysms is defined as ruptured abdominal aortic aneurysms or iliac aneurysms that occurrs during follow-up.

    Time frame: 12-month

  5. Secondary patency

    Secondary patency is defined as maintaining patency in the target vessel after a repeat intervention to correct complete occlusion in the treated arterial segment.

    Time frame: 12-month

  6. Secondary endovascular repair surgery

    Secondary endovascular repair is defined as secondary surgical intervention that occurrs during follow-up due to adverse events such as internal leakage and distal limb ischemia.

    Time frame: 12-month

06

Study locations

1 site
  • Renji Hospital
    Shanghai, Shanghai 200127, China
07

Registry details

Key details

Study ID
NCT06162273
Lead sponsor
RenJi Hospital
Responsible party
Sponsor
First posted
Dec 8, 2023
Start date
Dec 1, 2023 (estimated)
Primary completion
Dec 1, 2025 (estimated)
Completion
Dec 1, 2026 (estimated)
Last update
Dec 8, 2023

Study contacts

Guanhua Xue, M.D.
Contact
guanhuaxue@yeah.net
13585785270

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion